Retatrutide 12mg

Description

Strength: 12mg
CAS: 2381089-83-2
Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4845.444 g/mol
Peptide Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
Synonyms: Retatrutide acetate, LY3437943
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Retatrutide (12 mg) is an investigational, long-acting synthetic peptide originally developed by Eli Lilly and evaluated in Phase 2 and ongoing Phase 3 clinical research. It is classified as a triple-agonist peptide due to its simultaneous activity at the GLP-1, GIP, and glucagon receptors, positioning it as a next-generation compound in metabolic and cardiometabolic research.

Retatrutide (LY3437943) is a single-chain peptide composed of 39 amino acids, chemically modified with a fatty diacid moiety to enhance albumin binding and prolong systemic exposure. This acylation strategy has been studied for its ability to reduce renal clearance and support sustained receptor activation in both preclinical and clinical research models.

The retatrutide peptide has been investigated for its effects on body-weight regulation, glucose metabolism, insulin sensitivity, hepatic fat content, and energy expenditure. This product is supplied as a lyophilized powder in sterile, sealed vials and is intended strictly for laboratory research use. It is not approved for human or veterinary administration.

Researchers who buy retatrutide peptide typically do so for controlled investigational studies under regulated research protocols.

Retatrutide represents a novel class of multi-receptor metabolic research compounds. The 12 mg presentation corresponds to the highest dose evaluated in published Phase 2 clinical studies, making it an important reference point for ongoing research.

• Triple-agonist activity: Concurrent activation of GLP-1, GIP, and glucagon receptors
• Extended half-life: Approximately 6 days, supporting once-weekly dosing frameworks in research
• High purity and stability: Supplied as pharmaceutical-grade lyophilized peptide
• Primary research areas: Obesity, type 2 diabetes, insulin resistance, metabolic dysfunction, and hepatic fat regulation
• Documented clinical findings: Phase 2 studies reported up to 2% mean weight reduction at the 12 mg dose over 48 weeks
• Storage integrity: Maintained under refrigerated or frozen conditions to preserve peptide structure
• Regulatory status: Investigational compound; not FDA-approved. Qualified laboratories may order retatrutide peptide through authorized research suppliers

Retatrutide is being studied for its coordinated activation of three metabolic hormone receptors, producing synergistic effects relevant to metabolic research:

• GLP-1 receptor activation: Associated with appetite regulation, delayed gastric emptying, and glucose-dependent insulin secretion
• GIP receptor engagement: Studied for enhancement of insulin sensitivity and modulation of glucose-responsive pathways
• Glucagon receptor activation: Investigated for effects on energy expenditure, lipid metabolism, and hepatic fat utilization

Together, these mechanisms are examined for their combined influence on weight reduction, glycemic control, liver fat normalization, and cardiometabolic risk markers in both preclinical models and controlled human clinical trials.

In published Phase 2 clinical studies, retatrutide was evaluated using once-weekly dosing schedules, with doses escalating up to 12 mg over a 48-week treatment period. This represents the highest documented human exposure reported in peer-reviewed literature to date.

Reported research observations include:

• Significant reductions in body weight
• Improvements in insulin sensitivity and glucose regulation
• Substantial reductions in hepatic fat content
• Mild, transient increases in resting heart rate (approximately 5–10 bpm), attributed to glucagon receptor activity

All findings are derived from controlled clinical research. No dosing recommendations exist outside regulated clinical trial settings.

To preserve peptide integrity and experimental reliability:

• Lyophilized storage: Store at 2–8 °C, protected from light and moisture
• Long-term storage: Unopened vials may be stored at –20 °C to –80 °C
• After reconstitution: Refrigerate and do not refreeze; avoid repeated freeze–thaw cycles

Clinical studies have reported predominantly gastrointestinal adverse events, consistent with the profile of incretin-based compounds, while long-term safety remains under evaluation in ongoing trials. This product is not approved for therapeutic use and must only be handled by qualified research personnel.

References

https://pubmed.ncbi.nlm.nih.gov/37366315/

https://www.nature.com/articles/s41591-024-03018-2

https://pubmed.ncbi.nlm.nih.gov/37385280/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/

https://pubmed.ncbi.nlm.nih.gov/40291085/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.